Contact
searchSearch
HMP Global

Peripheral Arterial Disease

Features

Mike Watts, MD, FSIR
AMP 2026
When Economics Meets Innovation: Matching Deep Venous Arterialization to the Right Site of Service
08/07/2026
Mike Watts, MD, FSIR
08/07/2026
Vascular Disease Management
Dr Yana Etkin
AMP 2026
Early Detection and Timely Reintervention Drive Success After Deep Venous Arterialization
08/07/2026
Yana Etkin, MD, FSVS, FACS
Yana Etkin, MD,  presented an in-depth review of strategies for identifying and managing failing DVA, emphasizing that long-term success depends not only on creating the DVA circuit but also on maintaining its patency through vigilant...
Yana Etkin, MD,  presented an in-depth review of strategies for identifying and managing failing DVA, emphasizing that long-term success depends not only on creating the DVA circuit but also on maintaining its patency through vigilant...
Yana Etkin, MD,  presented an...
08/07/2026
Vascular Disease Management
Alik Farber, MD
AMP 2026
Four-Year BEST-CLI Data Reinforce a Team-Based Future for Limb Salvage
08/07/2026
Alik Farber, MD
Alik Farber, MD, MBA, presented the latest 4-year findings from the landmark BEST-CLI trial. He challenged attendees to move beyond the long-standing debate of surgery vs endovascular intervention and instead embrace an evidence-based,...
Alik Farber, MD, MBA, presented the latest 4-year findings from the landmark BEST-CLI trial. He challenged attendees to move beyond the long-standing debate of surgery vs endovascular intervention and instead embrace an evidence-based,...
Alik Farber, MD, MBA, presented...
08/07/2026
Vascular Disease Management
Dr Eric Secemsky
AMP 2026
Defining Optimal Medical Therapy for CLTI in 2026
08/07/2026
Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI
Dr Eric Secemsky presented a review of the evidence supporting contemporary medical management for patients with PAD and CLTI, emphasizing that pharmacologic therapy remains an essential pillar of reducing cardiovascular events.
Dr Eric Secemsky presented a review of the evidence supporting contemporary medical management for patients with PAD and CLTI, emphasizing that pharmacologic therapy remains an essential pillar of reducing cardiovascular events.
Dr Eric Secemsky presented a...
08/07/2026
Vascular Disease Management
Dr Ralf Langhoff
AMP 2026
Retrograde Access Moves to the Forefront: Rethinking CTO Crossing Strategies
08/06/2026
Ralf Langhoff, MD
During a Thursday afternoon session at the Amputation Prevention Symposium 2026, Ralf Langhoff, MD, asked attendees to reconsider when retrograde access should be used for chronic total occlusion (CTO) interventions.
During a Thursday afternoon session at the Amputation Prevention Symposium 2026, Ralf Langhoff, MD, asked attendees to reconsider when retrograde access should be used for chronic total occlusion (CTO) interventions.
During a Thursday afternoon...
08/06/2026
Vascular Disease Management
Dr Ramon Varcoe
AMP 2026
Bioresorbable Below-the-Knee Technology Shows Durable Promise for CLTI
08/06/2026
Ramon L. Varcoe, MBBS, MS, PhD
Dr Ramon L. Varcoe presented an update on bioresorbable BTK technology, highlighting the growing body of evidence supporting the Esprit™ BTK drug-eluting resorbable scaffold (Abbott Cardiovascular) for the treatment of CLTI.
Dr Ramon L. Varcoe presented an update on bioresorbable BTK technology, highlighting the growing body of evidence supporting the Esprit™ BTK drug-eluting resorbable scaffold (Abbott Cardiovascular) for the treatment of CLTI.
Dr Ramon L. Varcoe presented an...
08/06/2026
Vascular Disease Management
Dr Pradeep Nair
AMP 2026
A New Approach to Crossing and Preparing Complex Peripheral Chronic Total Occlusions
08/06/2026
Pradeep K. Nair, MD, FACC, FSCAI
Dr Pradeep K. Nair presented the clinical rationale, engineering design, pivotal clinical data, and early real-world experience with the Santreva-ATK Endovascular Revascularization Catheter (AngioSafe).
Dr Pradeep K. Nair presented the clinical rationale, engineering design, pivotal clinical data, and early real-world experience with the Santreva-ATK Endovascular Revascularization Catheter (AngioSafe).
Dr Pradeep K. Nair presented the...
08/06/2026
Vascular Disease Management
S Jay Mathews, MD
AMP 2026
SELUTION SLR Highlights the Growing Role of Sirolimus Drug-Eluting Balloons in CLTI
08/06/2026
S. Jay Mathews, MD, MS, FACC, FSCAI
This presentation examined the evolving evidence supporting the SELUTION SLR sirolimus drug-eluting balloon (Cordis) as a treatment strategy for femoropopliteal and BTK PAD, with particular emphasis on complex CLTI.
This presentation examined the evolving evidence supporting the SELUTION SLR sirolimus drug-eluting balloon (Cordis) as a treatment strategy for femoropopliteal and BTK PAD, with particular emphasis on complex CLTI.
This presentation examined the...
08/06/2026
Vascular Disease Management
Tim Wittig, MD
AMP 2026
MOTIV BTK Trial Demonstrates Promising Early Outcomes for Sirolimus-Eluting Bioresorbable Scaffold in CLTI
08/05/2026
Tim Wittig, MD
Tim Wittig, MD, presents the primary outcomes from the MOTIV BTK Trial, which evaluated the safety and efficacy of the sirolimus-eluting bioresorbable scaffold MOTIV BTK.
Tim Wittig, MD, presents the primary outcomes from the MOTIV BTK Trial, which evaluated the safety and efficacy of the sirolimus-eluting bioresorbable scaffold MOTIV BTK.
Tim Wittig, MD, presents the...
08/05/2026
Vascular Disease Management
Dr Eric Scott
AMP 2026
Using Imaging to Choose Between Endovascular Therapy and Surgical Bypass
08/05/2026
Eric C. Scott, MD
Dr Eric Scott presents presents a case-based discussion on how advanced vascular imaging should guide the decision between an endovascular-first or surgical bypass-first approach for patients with PAD and CLTI.
Dr Eric Scott presents presents a case-based discussion on how advanced vascular imaging should guide the decision between an endovascular-first or surgical bypass-first approach for patients with PAD and CLTI.
Dr Eric Scott presents presents...
08/05/2026
Vascular Disease Management
Dr Jos van den Berg
AMP 2026
What Data From a Pilot Study in Germany Tells Us About the Global Cost of CLTI
08/05/2026
Jos C. van den Berg, MD, PhD
Jos C. van den Berg, MD, PhD, presents findings from a pilot health economic analysis conducted in Germany that provides an important framework for understanding the true societal cost of CLTI.
Jos C. van den Berg, MD, PhD, presents findings from a pilot health economic analysis conducted in Germany that provides an important framework for understanding the true societal cost of CLTI.
Jos C. van den Berg, MD, PhD,...
08/05/2026
Vascular Disease Management

Videos

Dr S Jay Mathews speaks at ISET 2026
ISET 2026
Retrievable Scaffold Therapy: Results From Trials
04/07/2026
S. Jay Mathews, MD, MS, FACC, FSCAI
Dr Mathews reviews the latest clinical data, discusses evolving techniques, and highlights how retrievable scaffold technology is shaping the future of vascular intervention.
Dr Mathews reviews the latest clinical data, discusses evolving techniques, and highlights how retrievable scaffold technology is shaping the future of vascular intervention.
Dr Mathews reviews the latest...
04/07/2026
Vascular Disease Management
Dr Gunnar Tepe speaks at ISET 2026
ISET 2026
The State of DCB Technology in 2026: Where Are We Going?
03/31/2026
Gunnar Tepe, MD
Dr. Tepe explores the latest clinical data, emerging innovations, and ongoing challenges shaping the field, offering insight into how DCB technology is redefining endovascular treatment strategies today—and where it may lead.
Dr. Tepe explores the latest clinical data, emerging innovations, and ongoing challenges shaping the field, offering insight into how DCB technology is redefining endovascular treatment strategies today—and where it may lead.
Dr. Tepe explores the latest...
03/31/2026
Vascular Disease Management
Dr Marianne Brodmann speaks at ISET 2026
ISET 2026
Benefits of PTX: Insights from the TRUE-PTX Study
03/12/2026
Marianne Brodmann, MD
Dr. Brodmann reviews the results of the TRUE-PTX study, which compared paclitaxel drug-eluting and bare device treatment for PAD using real-world data design.
Dr. Brodmann reviews the results of the TRUE-PTX study, which compared paclitaxel drug-eluting and bare device treatment for PAD using real-world data design.
Dr. Brodmann reviews the results...
03/12/2026
Vascular Disease Management
McCall Walker, MD
Video Commentary
The Persistent Challenge of Peripheral Arterial Calcium
12/22/2025
McCall Walker, MD
In this video, McCall Walker, MD, discusses the article by Finn et al, "Dealing With Dense Calcium".
In this video, McCall Walker, MD, discusses the article by Finn et al, "Dealing With Dense Calcium".
In this video, McCall Walker,...
12/22/2025
Vascular Disease Management
Interview With Viet Le, DMSc, MPAS, PA-C, FACC, FAHA, HF-Cert
Videos
Prevalence of Atrial Fibrillation Increases Major Adverse Cardiovascular Events, Particularly Heart Failure Hospitalization in Patients With Peripheral Arterial Disease
11/18/2025
Viet Le, PA-C, FACC, FAHA; Isabel Vega
Watch as Viet Le, DMSc, MPAS, PA-C, FACC, FAHA, HF-Cert, discusses his abstract from AHA 2025.
Watch as Viet Le, DMSc, MPAS, PA-C, FACC, FAHA, HF-Cert, discusses his abstract from AHA 2025.
Watch as Viet Le, DMSc, MPAS,...
11/18/2025
EP Lab Digest
Dr Nakama
AMP 2025
One-Year Outcomes of Drug-Eluting Stent vs Drug-Coated Balloon for Femoropopliteal Artery Lesions: The BEASTARS Study Results
10/08/2025
Tatsuya Nakama, MD
In this video recorded at AMP 2025, Tatsuya Nakama, MD, discusses his AMP presentation on 1-year results from the BEASTARS study.
In this video recorded at AMP 2025, Tatsuya Nakama, MD, discusses his AMP presentation on 1-year results from the BEASTARS study.
In this video recorded at AMP...
10/08/2025
Vascular Disease Management
Video
Saving Limbs, Saving Lives, and Reducing Healthcare Costs With DVA
09/19/2025
Craig M. Walker, MD, FACC, FACP, FSCAI, FCCP
In this video, Clinical Editor Craig Walker, MD, comments on an article from the September issue article entitled “Deep Vein Arterialization for No-Option Chronic Limb-Threatening Ischemia: An Overview of the LimFlow System and CLariTI Study."
In this video, Clinical Editor Craig Walker, MD, comments on an article from the September issue article entitled “Deep Vein Arterialization for No-Option Chronic Limb-Threatening Ischemia: An Overview of the LimFlow System and CLariTI Study."
In this video, Clinical Editor...
09/19/2025
Vascular Disease Management
Mike Watts, MD
AMP 2025
Will AI and Wearables Change the Future of CLTI Therapy?
09/18/2025
Mike Watts, MD, FSIR
Mike Watts, MD, FSIR, discusses his presentation on the use of wearables and artificial intelligence in the prevention and treatment of chronic limb-threatening ischemia.
Mike Watts, MD, FSIR, discusses his presentation on the use of wearables and artificial intelligence in the prevention and treatment of chronic limb-threatening ischemia.
Mike Watts, MD, FSIR, discusses...
09/18/2025
Vascular Disease Management
Dr Madassery
AMP 2025
CLTI Imaging: When and What I Look at Before Angio and on the Angio
09/10/2025
Kumar Madassery, MD
Dr Kumar Madassery discusses his AMP 2025 presentation on angiography for patients with chronic limb-threatening ischemia.
Dr Kumar Madassery discusses his AMP 2025 presentation on angiography for patients with chronic limb-threatening ischemia.
Dr Kumar Madassery discusses his...
09/10/2025
Vascular Disease Management
Bret Wiechmann, MD
OBL Corner
Is There an Optimal Site of Service for CLTI Intervention: Hospital, ASC, or OBL?
09/04/2025
Bret N. Wiechmann, MD, FSIR, FAHA; Mike Watts, MD, FSIR
Drs Bret Wiechmann and Mike Watts discuss the differences between hospitals, ambulatory surgery centers, and office-based labs when dealing with CLTI interventions.
Drs Bret Wiechmann and Mike Watts discuss the differences between hospitals, ambulatory surgery centers, and office-based labs when dealing with CLTI interventions.
Drs Bret Wiechmann and Mike...
09/04/2025
Vascular Disease Management
Ghassan Abou-Alfa headshot
ASCO 2026
Immunotherapy Plus TACE Emerges as a New Option for Intermediate-Stage Hepatocellular Carcinoma
07/13/2026
Ghassan Abou-Alfa, MD, MBA
Ghassan Abou-Alfa, MD, discusses phase 3 EMERALD-3 results showing that adding STRIDE (tremelimumab plus durvalumab) to transarterial chemoembolization significantly improved progression-free survival in patients with unresectable...
Ghassan Abou-Alfa, MD, discusses phase 3 EMERALD-3 results showing that adding STRIDE (tremelimumab plus durvalumab) to transarterial chemoembolization significantly improved progression-free survival in patients with unresectable...
Ghassan Abou-Alfa, MD, discusses...
07/13/2026
Vascular Disease Management
Michael Pishvaian headshot
Interview
Intra-Arterial Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
06/15/2026
Michael Pishvaian, MD, PhD
Michael Pishvaian, MD, PhD, discusses the phase 3 TIGeR-PaC study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
Michael Pishvaian, MD, PhD, discusses the phase 3 TIGeR-PaC study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
Michael Pishvaian, MD, PhD,...
06/15/2026
Vascular Disease Management
Dr Kak Khee Yeung speaks at ISET 2026.
ISET 2026
Can AI Be of Value in Predicting Type B Dissection Progression Over Time?
04/16/2026
Kak Khee Yeung, MD, PhD
Kak Khee Yeung, MD, PhD, explores the potential role of AI in predicting the progression of Type B aortic dissection over time.
Kak Khee Yeung, MD, PhD, explores the potential role of AI in predicting the progression of Type B aortic dissection over time.
Kak Khee Yeung, MD, PhD,...
04/16/2026
Vascular Disease Management
Dr Mouawad speaks at ISET 2026
ISET 2026
Advancing Thrombectomy and Autologous Blood Reinfusion for Pulmonary Embolism Treatment: Results from the AVENTUS Pivotal Study
04/09/2026
Nicolas J. Mouawad, MD, MPH, MBA
Dr Mouawad discusses the results of the AVENTUS pivotal trial.
Dr Mouawad discusses the results of the AVENTUS pivotal trial.
Dr Mouawad discusses the results...
04/09/2026
Vascular Disease Management
Dr S Jay Mathews speaks at ISET 2026
ISET 2026
Retrievable Scaffold Therapy: Results From Trials
04/07/2026
S. Jay Mathews, MD, MS, FACC, FSCAI
Dr Mathews reviews the latest clinical data, discusses evolving techniques, and highlights how retrievable scaffold technology is shaping the future of vascular intervention.
Dr Mathews reviews the latest clinical data, discusses evolving techniques, and highlights how retrievable scaffold technology is shaping the future of vascular intervention.
Dr Mathews reviews the latest...
04/07/2026
Vascular Disease Management
Dr Mary Costantino speaks at ISET 2026.
ISET 2026
Uterine Fibroid Embolization in the OBL: Patient Selection and Workflow Optimization
04/02/2026
Mary Costantino, MD, FSIR
Dr Costantino outlines practical strategies for identifying appropriate candidates and streamlining procedural workflows in the OBL setting, with a focus on improving efficiency, patient outcomes, and overall practice success.
Dr Costantino outlines practical strategies for identifying appropriate candidates and streamlining procedural workflows in the OBL setting, with a focus on improving efficiency, patient outcomes, and overall practice success.
Dr Costantino outlines practical...
04/02/2026
Vascular Disease Management
Dr Salazar speaks at ISET 2026
ISET 2026
Venous Valve Technology: When Will It Be Standard of Care?
04/01/2026
Gloria Salazar, MD, FSIR
Dr Salazar examines the current state of venous valve technologies, including recent clinical progress and the challenges that remain before widespread adoption.
Dr Salazar examines the current state of venous valve technologies, including recent clinical progress and the challenges that remain before widespread adoption.
Dr Salazar examines the current...
04/01/2026
Vascular Disease Management
Dr Gunnar Tepe speaks at ISET 2026
ISET 2026
The State of DCB Technology in 2026: Where Are We Going?
03/31/2026
Gunnar Tepe, MD
Dr. Tepe explores the latest clinical data, emerging innovations, and ongoing challenges shaping the field, offering insight into how DCB technology is redefining endovascular treatment strategies today—and where it may lead.
Dr. Tepe explores the latest clinical data, emerging innovations, and ongoing challenges shaping the field, offering insight into how DCB technology is redefining endovascular treatment strategies today—and where it may lead.
Dr. Tepe explores the latest...
03/31/2026
Vascular Disease Management
Dr Jacques Busquet speaks at ISET 2026.
ISET 2026
The Mystery of Post-EVAR Endotension
03/26/2026
Jacques Busquet, MD
In this video, renowned cardiovascular and endovascular surgeon Jacques Busquet, MD, from Clinique Val d'Or in Paris, France, explores the mystery of post-EVAR endotension, expanding on insights from his presentation at ISET 2026.
In this video, renowned cardiovascular and endovascular surgeon Jacques Busquet, MD, from Clinique Val d'Or in Paris, France, explores the mystery of post-EVAR endotension, expanding on insights from his presentation at ISET 2026.
In this video, renowned...
03/26/2026
Vascular Disease Management
Dr Sanjay Misra speaks at ISET 2026
ISET 2026
Renal Denervation for Refractory Hypertension: Indications, Data, and Outcomes
03/25/2026
Sanjay Misra, MD, FSIR, FAHA, FACR
Interventional radiologist Sanjay Misra, MD, FSIR, FAHA, FACR, from the Mayo Clinic, highlights key insights from his presentation on renal denervation for hypertension.
Interventional radiologist Sanjay Misra, MD, FSIR, FAHA, FACR, from the Mayo Clinic, highlights key insights from his presentation on renal denervation for hypertension.
Interventional radiologist...
03/25/2026
Vascular Disease Management

Presentations

Mike Watts, MD, FSIR
AMP 2026
When Economics Meets Innovation: Matching Deep Venous Arterialization to the Right Site of Service
08/07/2026
Mike Watts, MD, FSIR
08/07/2026
Vascular Disease Management
Dr Yana Etkin
AMP 2026
Early Detection and Timely Reintervention Drive Success After Deep Venous Arterialization
08/07/2026
Yana Etkin, MD, FSVS, FACS
Yana Etkin, MD,  presented an in-depth review of strategies for identifying and managing failing DVA, emphasizing that long-term success depends not only on creating the DVA circuit but also on maintaining its patency through vigilant...
Yana Etkin, MD,  presented an in-depth review of strategies for identifying and managing failing DVA, emphasizing that long-term success depends not only on creating the DVA circuit but also on maintaining its patency through vigilant...
Yana Etkin, MD,  presented an...
08/07/2026
Vascular Disease Management
Alik Farber, MD
AMP 2026
Four-Year BEST-CLI Data Reinforce a Team-Based Future for Limb Salvage
08/07/2026
Alik Farber, MD
Alik Farber, MD, MBA, presented the latest 4-year findings from the landmark BEST-CLI trial. He challenged attendees to move beyond the long-standing debate of surgery vs endovascular intervention and instead embrace an evidence-based,...
Alik Farber, MD, MBA, presented the latest 4-year findings from the landmark BEST-CLI trial. He challenged attendees to move beyond the long-standing debate of surgery vs endovascular intervention and instead embrace an evidence-based,...
Alik Farber, MD, MBA, presented...
08/07/2026
Vascular Disease Management
Dr Eric Secemsky
AMP 2026
Defining Optimal Medical Therapy for CLTI in 2026
08/07/2026
Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI
Dr Eric Secemsky presented a review of the evidence supporting contemporary medical management for patients with PAD and CLTI, emphasizing that pharmacologic therapy remains an essential pillar of reducing cardiovascular events.
Dr Eric Secemsky presented a review of the evidence supporting contemporary medical management for patients with PAD and CLTI, emphasizing that pharmacologic therapy remains an essential pillar of reducing cardiovascular events.
Dr Eric Secemsky presented a...
08/07/2026
Vascular Disease Management
Dr Ralf Langhoff
AMP 2026
Retrograde Access Moves to the Forefront: Rethinking CTO Crossing Strategies
08/06/2026
Ralf Langhoff, MD
During a Thursday afternoon session at the Amputation Prevention Symposium 2026, Ralf Langhoff, MD, asked attendees to reconsider when retrograde access should be used for chronic total occlusion (CTO) interventions.
During a Thursday afternoon session at the Amputation Prevention Symposium 2026, Ralf Langhoff, MD, asked attendees to reconsider when retrograde access should be used for chronic total occlusion (CTO) interventions.
During a Thursday afternoon...
08/06/2026
Vascular Disease Management
Dr Ramon Varcoe
AMP 2026
Bioresorbable Below-the-Knee Technology Shows Durable Promise for CLTI
08/06/2026
Ramon L. Varcoe, MBBS, MS, PhD
Dr Ramon L. Varcoe presented an update on bioresorbable BTK technology, highlighting the growing body of evidence supporting the Esprit™ BTK drug-eluting resorbable scaffold (Abbott Cardiovascular) for the treatment of CLTI.
Dr Ramon L. Varcoe presented an update on bioresorbable BTK technology, highlighting the growing body of evidence supporting the Esprit™ BTK drug-eluting resorbable scaffold (Abbott Cardiovascular) for the treatment of CLTI.
Dr Ramon L. Varcoe presented an...
08/06/2026
Vascular Disease Management
Dr Pradeep Nair
AMP 2026
A New Approach to Crossing and Preparing Complex Peripheral Chronic Total Occlusions
08/06/2026
Pradeep K. Nair, MD, FACC, FSCAI
Dr Pradeep K. Nair presented the clinical rationale, engineering design, pivotal clinical data, and early real-world experience with the Santreva-ATK Endovascular Revascularization Catheter (AngioSafe).
Dr Pradeep K. Nair presented the clinical rationale, engineering design, pivotal clinical data, and early real-world experience with the Santreva-ATK Endovascular Revascularization Catheter (AngioSafe).
Dr Pradeep K. Nair presented the...
08/06/2026
Vascular Disease Management
S Jay Mathews, MD
AMP 2026
SELUTION SLR Highlights the Growing Role of Sirolimus Drug-Eluting Balloons in CLTI
08/06/2026
S. Jay Mathews, MD, MS, FACC, FSCAI
This presentation examined the evolving evidence supporting the SELUTION SLR sirolimus drug-eluting balloon (Cordis) as a treatment strategy for femoropopliteal and BTK PAD, with particular emphasis on complex CLTI.
This presentation examined the evolving evidence supporting the SELUTION SLR sirolimus drug-eluting balloon (Cordis) as a treatment strategy for femoropopliteal and BTK PAD, with particular emphasis on complex CLTI.
This presentation examined the...
08/06/2026
Vascular Disease Management
Tim Wittig, MD
AMP 2026
MOTIV BTK Trial Demonstrates Promising Early Outcomes for Sirolimus-Eluting Bioresorbable Scaffold in CLTI
08/05/2026
Tim Wittig, MD
Tim Wittig, MD, presents the primary outcomes from the MOTIV BTK Trial, which evaluated the safety and efficacy of the sirolimus-eluting bioresorbable scaffold MOTIV BTK.
Tim Wittig, MD, presents the primary outcomes from the MOTIV BTK Trial, which evaluated the safety and efficacy of the sirolimus-eluting bioresorbable scaffold MOTIV BTK.
Tim Wittig, MD, presents the...
08/05/2026
Vascular Disease Management
Dr Eric Scott
AMP 2026
Using Imaging to Choose Between Endovascular Therapy and Surgical Bypass
08/05/2026
Eric C. Scott, MD
Dr Eric Scott presents presents a case-based discussion on how advanced vascular imaging should guide the decision between an endovascular-first or surgical bypass-first approach for patients with PAD and CLTI.
Dr Eric Scott presents presents a case-based discussion on how advanced vascular imaging should guide the decision between an endovascular-first or surgical bypass-first approach for patients with PAD and CLTI.
Dr Eric Scott presents presents...
08/05/2026
Vascular Disease Management
Mike Watts, MD, FSIR
AMP 2026
When Economics Meets Innovation: Matching Deep Venous Arterialization to the Right Site of Service
08/07/2026
Mike Watts, MD, FSIR
08/07/2026
Vascular Disease Management
Dr Yana Etkin
AMP 2026
Early Detection and Timely Reintervention Drive Success After Deep Venous Arterialization
08/07/2026
Yana Etkin, MD, FSVS, FACS
Yana Etkin, MD,  presented an in-depth review of strategies for identifying and managing failing DVA, emphasizing that long-term success depends not only on creating the DVA circuit but also on maintaining its patency through vigilant...
Yana Etkin, MD,  presented an in-depth review of strategies for identifying and managing failing DVA, emphasizing that long-term success depends not only on creating the DVA circuit but also on maintaining its patency through vigilant...
Yana Etkin, MD,  presented an...
08/07/2026
Vascular Disease Management
Alik Farber, MD
AMP 2026
Four-Year BEST-CLI Data Reinforce a Team-Based Future for Limb Salvage
08/07/2026
Alik Farber, MD
Alik Farber, MD, MBA, presented the latest 4-year findings from the landmark BEST-CLI trial. He challenged attendees to move beyond the long-standing debate of surgery vs endovascular intervention and instead embrace an evidence-based,...
Alik Farber, MD, MBA, presented the latest 4-year findings from the landmark BEST-CLI trial. He challenged attendees to move beyond the long-standing debate of surgery vs endovascular intervention and instead embrace an evidence-based,...
Alik Farber, MD, MBA, presented...
08/07/2026
Vascular Disease Management
Dr Eric Secemsky
AMP 2026
Defining Optimal Medical Therapy for CLTI in 2026
08/07/2026
Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI
Dr Eric Secemsky presented a review of the evidence supporting contemporary medical management for patients with PAD and CLTI, emphasizing that pharmacologic therapy remains an essential pillar of reducing cardiovascular events.
Dr Eric Secemsky presented a review of the evidence supporting contemporary medical management for patients with PAD and CLTI, emphasizing that pharmacologic therapy remains an essential pillar of reducing cardiovascular events.
Dr Eric Secemsky presented a...
08/07/2026
Vascular Disease Management
Dr Ralf Langhoff
AMP 2026
Retrograde Access Moves to the Forefront: Rethinking CTO Crossing Strategies
08/06/2026
Ralf Langhoff, MD
During a Thursday afternoon session at the Amputation Prevention Symposium 2026, Ralf Langhoff, MD, asked attendees to reconsider when retrograde access should be used for chronic total occlusion (CTO) interventions.
During a Thursday afternoon session at the Amputation Prevention Symposium 2026, Ralf Langhoff, MD, asked attendees to reconsider when retrograde access should be used for chronic total occlusion (CTO) interventions.
During a Thursday afternoon...
08/06/2026
Vascular Disease Management
Dr Ramon Varcoe
AMP 2026
Bioresorbable Below-the-Knee Technology Shows Durable Promise for CLTI
08/06/2026
Ramon L. Varcoe, MBBS, MS, PhD
Dr Ramon L. Varcoe presented an update on bioresorbable BTK technology, highlighting the growing body of evidence supporting the Esprit™ BTK drug-eluting resorbable scaffold (Abbott Cardiovascular) for the treatment of CLTI.
Dr Ramon L. Varcoe presented an update on bioresorbable BTK technology, highlighting the growing body of evidence supporting the Esprit™ BTK drug-eluting resorbable scaffold (Abbott Cardiovascular) for the treatment of CLTI.
Dr Ramon L. Varcoe presented an...
08/06/2026
Vascular Disease Management
Dr Pradeep Nair
AMP 2026
A New Approach to Crossing and Preparing Complex Peripheral Chronic Total Occlusions
08/06/2026
Pradeep K. Nair, MD, FACC, FSCAI
Dr Pradeep K. Nair presented the clinical rationale, engineering design, pivotal clinical data, and early real-world experience with the Santreva-ATK Endovascular Revascularization Catheter (AngioSafe).
Dr Pradeep K. Nair presented the clinical rationale, engineering design, pivotal clinical data, and early real-world experience with the Santreva-ATK Endovascular Revascularization Catheter (AngioSafe).
Dr Pradeep K. Nair presented the...
08/06/2026
Vascular Disease Management
S Jay Mathews, MD
AMP 2026
SELUTION SLR Highlights the Growing Role of Sirolimus Drug-Eluting Balloons in CLTI
08/06/2026
S. Jay Mathews, MD, MS, FACC, FSCAI
This presentation examined the evolving evidence supporting the SELUTION SLR sirolimus drug-eluting balloon (Cordis) as a treatment strategy for femoropopliteal and BTK PAD, with particular emphasis on complex CLTI.
This presentation examined the evolving evidence supporting the SELUTION SLR sirolimus drug-eluting balloon (Cordis) as a treatment strategy for femoropopliteal and BTK PAD, with particular emphasis on complex CLTI.
This presentation examined the...
08/06/2026
Vascular Disease Management
Tim Wittig, MD
AMP 2026
MOTIV BTK Trial Demonstrates Promising Early Outcomes for Sirolimus-Eluting Bioresorbable Scaffold in CLTI
08/05/2026
Tim Wittig, MD
Tim Wittig, MD, presents the primary outcomes from the MOTIV BTK Trial, which evaluated the safety and efficacy of the sirolimus-eluting bioresorbable scaffold MOTIV BTK.
Tim Wittig, MD, presents the primary outcomes from the MOTIV BTK Trial, which evaluated the safety and efficacy of the sirolimus-eluting bioresorbable scaffold MOTIV BTK.
Tim Wittig, MD, presents the...
08/05/2026
Vascular Disease Management
Dr Eric Scott
AMP 2026
Using Imaging to Choose Between Endovascular Therapy and Surgical Bypass
08/05/2026
Eric C. Scott, MD
Dr Eric Scott presents presents a case-based discussion on how advanced vascular imaging should guide the decision between an endovascular-first or surgical bypass-first approach for patients with PAD and CLTI.
Dr Eric Scott presents presents a case-based discussion on how advanced vascular imaging should guide the decision between an endovascular-first or surgical bypass-first approach for patients with PAD and CLTI.
Dr Eric Scott presents presents...
08/05/2026
Vascular Disease Management

Stay in the Know

Vascular Disease Management Newsletter

News

BTK Treatment for CLTI
Medical University of Graz Enrolls First Patient in DEEPER CHALLENGE Trial Evaluating Spur® Peripheral Retrievable Scaffold System in a Select CLTI Cohort
07/02/2026
SAN CLEMENTE, CA — Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported...
SAN CLEMENTE, CA — Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported...
SAN CLEMENTE, CA — Reflow...
07/02/2026
Vascular Disease Management
Drug-Coated Balloons
SirPAD: Primary Results Confirm the Safety and Efficacy of Sirolimus Coated Balloon in PAD
03/31/2026
Tampa, Florida – Concept Medical Inc. (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the presentation of the world’s largest randomised controlled trial of a Sirolimus-coated...
Tampa, Florida – Concept Medical Inc. (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the presentation of the world’s largest randomised controlled trial of a Sirolimus-coated...
Tampa, Florida – Concept Medical...
03/31/2026
Vascular Disease Management
Peripheral Arterial Disease
CIS and Terrebonne General Are First in Louisiana to Use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter
01/09/2026
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
JANUARY 8, 2026 –HOUMA, LA...
01/09/2026
Vascular Disease Management
intravascular lithotripsy
FastWave Medical Names Leading Vascular Specialists as Principal Investigators for Peripheral IVL Trial
10/02/2025
The study will evaluate the safety and effectiveness of the Artero™ IVL system in treating peripheral arterial disease (PAD) and support FastWave's ultimate path to FDA clearance.
The study will evaluate the safety and effectiveness of the Artero™ IVL system in treating peripheral arterial disease (PAD) and support FastWave's ultimate path to FDA clearance.
The study will evaluate the...
10/02/2025
Vascular Disease Management
Retrievable Stents
CIS and Terrebonne General are First in Louisiana to Use the Spur® Peripheral Retrievable Stent System to Treat Artery Disease Below the Knee
06/16/2025
JUNE 16, 2025 – HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the Spur® Peripheral Retrievable Stent System to treat chronic...
JUNE 16, 2025 – HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the Spur® Peripheral Retrievable Stent System to treat chronic...
JUNE 16, 2025 – HOUMA, LA –...
06/16/2025
Vascular Disease Management
VAM25
New Study Finds GLP-1 Medications Decrease Risk of Major Cardiovascular Events and Amputations for Patients With Moderate Peripheral Artery Disease
06/06/2025
NEW ORLEANS, LA, JUNE 6, 2025 – A large retrospective review of over 100,000 patients found the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in moderate peripheral artery disease (PAD) is associated with a decreased rate of...
NEW ORLEANS, LA, JUNE 6, 2025 – A large retrospective review of over 100,000 patients found the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in moderate peripheral artery disease (PAD) is associated with a decreased rate of...
NEW ORLEANS, LA, JUNE 6, 2025 –...
06/06/2025
Vascular Disease Management
Drug-Coated Balloons
Cardiovascular Institute of the South Is First in the World to Use New Drug-Coated Balloon to Treat Leg Artery Blockages
05/27/2025
May 24, 2024 – Lafayette, LA – Cardiovascular Institute of the South (CIS) is the first in the world to use the 200-cm RANGER Drug-Coated Balloon to treat peripheral artery disease (PAD) in the legs. CIS interventional cardiologist Dr....
May 24, 2024 – Lafayette, LA – Cardiovascular Institute of the South (CIS) is the first in the world to use the 200-cm RANGER Drug-Coated Balloon to treat peripheral artery disease (PAD) in the legs. CIS interventional cardiologist Dr....
May 24, 2024 – Lafayette,...
05/27/2025
Vascular Disease Management
Lower-extremity intervention
First Patient Treated in ELITE-BTK Pivotal Trial for Below-the-Knee PAD Using R3 Vascular's Magnitude Drug-Eluting Bioresorbable Scaffold
04/22/2025
The first patient in its ELITE-BTK pivotal trial was treated by Dr. Brian DeRubertis, FACS, Chief of the Division of Vascular & Endovascular Surgery at NewYork-Presbyterian and Weill Cornell Medicine in New York City.
The first patient in its ELITE-BTK pivotal trial was treated by Dr. Brian DeRubertis, FACS, Chief of the Division of Vascular & Endovascular Surgery at NewYork-Presbyterian and Weill Cornell Medicine in New York City.
The first patient in its...
04/22/2025
Cath Lab Digest
Restenosis
Real-world Data Shows Cook’s Zilver PTX Leads to Lower Rates of In-stent Occlusion Than Boston Scientific’s Eluvia
03/27/2025
Bloomington, Ind. — Cook Medical’s Zilver PTX drug-eluting stent (DES) has lower rates of in-stent occlusions among patients with restenosis at 3 years than Boston Scientific’s Eluvia DES, according to real-world data from the REALDES study....
Bloomington, Ind. — Cook Medical’s Zilver PTX drug-eluting stent (DES) has lower rates of in-stent occlusions among patients with restenosis at 3 years than Boston Scientific’s Eluvia DES, according to real-world data from the REALDES study....
Bloomington, Ind. — Cook...
03/27/2025
Vascular Disease Management
Critical Limb Ischemia
AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia
01/30/2025
The Auryon laser can be used to treat all infrainguinal lesion types, including above-the-knee (ATK), below-the-knee (BTK) and In-Stent Restenosis (ISR)3-6 and to date, it has been used to treat more than 100,000 patients7 in the United...
The Auryon laser can be used to treat all infrainguinal lesion types, including above-the-knee (ATK), below-the-knee (BTK) and In-Stent Restenosis (ISR)3-6 and to date, it has been used to treat more than 100,000 patients7 in the United...
The Auryon laser can be used to...
01/30/2025
Vascular Disease Management
Press Release
Fluidx Completes Submission of Premarket Approval Application for the GPX® Embolic Device
07/24/2026
Salt Lake City (UT) – 07/24/2026 Fluidx Medical Technology, Inc., a clinical stage medical device company advancing its portfolio of embolic technologies, announced that it recently submitted to the U.S. Food and Drug Administration (FDA) the...
Salt Lake City (UT) – 07/24/2026 Fluidx Medical Technology, Inc., a clinical stage medical device company advancing its portfolio of embolic technologies, announced that it recently submitted to the U.S. Food and Drug Administration (FDA) the...
Salt Lake City (UT) – 07/24/2026...
07/24/2026
Vascular Disease Management
Thrombectomy
THUNDER Study Demonstrates Penumbra’s THUNDERBOLT is Safe and Effective for Stroke Care
07/22/2026
ALAMEDA, Calif. – Penumbra, Inc. announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company’s novel...
ALAMEDA, Calif. – Penumbra, Inc. announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company’s novel...
ALAMEDA, Calif....
07/22/2026
Cath Lab Digest
Stroke Interventions
Imperative Care Launches Ikon 24 Pro Guidewire, Enhancing the Zoom Stroke System to Support More Efficient Stroke Procedures
07/17/2026
CAMPBELL, Calif., July 16, 2026 — Imperative Care, a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the launch of the Ikon™ 24 Pro Guidewire, a next-generation...
CAMPBELL, Calif., July 16, 2026 — Imperative Care, a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the launch of the Ikon™ 24 Pro Guidewire, a next-generation...
CAMPBELL, Calif., July 16, 2026...
07/17/2026
Vascular Disease Management
Liver Tumor Ablation
First Meta-analysis Supports Histotripsy for Liver Tumor Ablation
07/14/2026
Laura Simson, MA
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high...
07/14/2026
Vascular Disease Management
Radiation Safety
Landmark Multi-Society Consensus Signals New Era in Occupational Radiation Safety; Rampart Positioned to Accelerate Adoption of Lead-Free Enhanced Radiation Protection
07/14/2026
BIRMINGHAM, Ala. — July 14, 2026 — Rampart, the global leader in enhanced radiation protection devices (ERPD), today welcomed the publication of a landmark multi-society expert consensus statement that calls for a fundamental shift in...
BIRMINGHAM, Ala. — July 14, 2026 — Rampart, the global leader in enhanced radiation protection devices (ERPD), today welcomed the publication of a landmark multi-society expert consensus statement that calls for a fundamental shift in...
BIRMINGHAM, Ala. — July 14, 2026...
07/14/2026
Vascular Disease Management
GPX Embolic Device
GPX® Embolic Device Meets Primary Endpoints in an Investigational Device Exemption (IDE) Pivotal Trial
07/14/2026
Salt Lake City (UT) – Fluidx Medical Technology, Inc. announced the positive results from the Investigational Device Exemption (IDE) pivotal clinical trial evaluating the GPX Embolic Device. In the 114 patients that were treated in the trial,...
Salt Lake City (UT) – Fluidx Medical Technology, Inc. announced the positive results from the Investigational Device Exemption (IDE) pivotal clinical trial evaluating the GPX Embolic Device. In the 114 patients that were treated in the trial,...
Salt Lake City (UT) – Fluidx...
07/14/2026
Vascular Disease Management
Transarterial Chemoembolization
STRIDE-Based Regimens Plus TACE Improve Outcomes vs TACE Alone in Embolization-Eligible Hepatocellular Carcinoma
07/13/2026
Stephanie Holland
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Results from the phase 3...
07/13/2026
Vascular Disease Management
Peripheral Intervention
3-Year DETOUR2 Results Demonstrate Sustained Symptom Relief and Limb Preservation in Complex SFA Disease
07/09/2026
Data from one of the first studies in long-segment (>30 cm) FP disease show durable patency, low reintervention rate, and high limb salvage through 36 months.
Data from one of the first studies in long-segment (>30 cm) FP disease show durable patency, low reintervention rate, and high limb salvage through 36 months.
Data from one of the first...
07/09/2026
Cath Lab Digest
Thrombectomy for Stroke
First Patient Enrolled in Penumbra’s FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke
07/07/2026
ALAMEDA, Calif. - Penumbra, Inc. announced the initiation of its FORWARD study, an international, real world prospective, multi-center study. The study will collect safety and efficacy data on mechanical thrombectomy, including computer...
ALAMEDA, Calif. - Penumbra, Inc. announced the initiation of its FORWARD study, an international, real world prospective, multi-center study. The study will collect safety and efficacy data on mechanical thrombectomy, including computer...
ALAMEDA, Calif. - Penumbra, Inc....
07/07/2026
Cath Lab Digest
Embolization
Fluidx Announces Continued Clinical Success with ULTRA Embolic Gel
07/02/2026
SALT LAKE CITY, UT — July 02, 2026 — Fluidx Medical Technology, Inc. today announced that its ULTRA Embolic Device continues to see clinical success and was most recently used to treat a large, right-sided renal cell carcinoma (RCC) tumor at...
SALT LAKE CITY, UT — July 02, 2026 — Fluidx Medical Technology, Inc. today announced that its ULTRA Embolic Device continues to see clinical success and was most recently used to treat a large, right-sided renal cell carcinoma (RCC) tumor at...
SALT LAKE CITY, UT — July 02,...
07/02/2026
Vascular Disease Management

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use